Researchers studied 55 patients with locally advanced esophageal squamous cell carcinoma. They compared two treatment approaches involving chemotherapy followed by surgery. One group received standard chemotherapy, while the other received a combination of chemotherapy and an immune checkpoint inhibitor called camrelizumab.
The study looked at how immune cells changed over time in patients who responded to treatment versus those who did not. Responders showed specific changes in immune cell populations, such as an expansion of memory T cells. In contrast, non-responders failed to develop effective antitumor immunity and showed persistent expression of targetable tumor-associated antigens.
The main reason to be careful is that this involved a small group of 55 patients, which limits how broadly these results can be applied. The findings support the development of new therapies, such as vaccines targeting tumor antigens, to help overcome resistance in patients who do not respond to current treatments.